| Filed On | Filing |
|---|---|
| 23 Oct 2026 |
8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 15 Oct 2026 |
8-K: Other Events
On October 15, 2026, Edesa Biotech, Inc. (the “Company”) reported that the U.S. Food and Drug Administration (“FDA”) has cleared the Company's Investigational New Drug (“IND”) application for its Phase 2 clinical study of EB06 in vitilig... |
| 06 Oct 2026 |
Form 4: Nijhawan Pardeep, Director
Received 6,893 shares as a grant or award |
| 01 Sep 2026 |
Form 4: Nijhawan Pardeep, Director
Received 5,714 shares as a grant or award |
| 26 Aug 2026 | SCHEDULE 13G |
| 25 Aug 2026 | SCHEDULE 13D/A |
| 25 Aug 2026 | SCHEDULE 13D/A |
| 20 Aug 2026 | 424B5 |
| 20 Aug 2026 | 8-K: Entry into a Material Definitive Agreement; Other Events |
| 19 Aug 2026 | 424B5 |
| 13 Aug 2026 | FORM 10-Q |
| 13 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 04 Aug 2026 |
Form 4: Nijhawan Pardeep, Director
Received 5,324 shares as a grant or award |
| 13 Jul 2026 | EFFECT |
| 13 Jul 2026 | FORM 424B3 |
| 02 Jul 2026 |
Form 4: Nijhawan Pardeep, Director
Received 3,378 shares as a grant or award |
| 02 Jul 2026 | FORM S-3 |
| 26 Jun 2026 | D |
| 18 Jun 2026 | SCHEDULE 13G |
| 16 Jun 2026 | SCHEDULE 13D/A |
Loading...
